[Public Notices]Society for Immunotherapy of Cancer (SITC) 2022 Poster Presentation

11 Nov 2022
제목Society for Immunotherapy of Cancer (SITC) 2022 Poster Presentation
참고Public Notices

PharmAbcine’s e-poster presentation is currently available at Society for Immunotherapy of Cancer (SITC) 2022 website.

The e-poster includes new data of PMC-309, one of the Company’s first immuno-oncology assets. Through the newly presented PK and GLP-Tox data demonstrate that the molecule has its safety profile established and is ready for the entry into clinical trial.

The registered members may access the poster on the SITC website virtual platform (https://2022.sitc.showcare.io/). The details of the presentation are as follows:

Title: PMC-309, a highly selective anti-VISTA antibody reverses immunosuppressive TME to immune-supportive TME

Abstract Number: 751

Presentation Type: Poster Presentation

Onsite Location: Poster Hall

■ Please check the attached files for full texts and summary of the presentation.

     2F, Research Building 2, 70,

     Yuseong-daero 1689 beon-gil,
     Yuseong-gu, Daejeon, 34047, Republic of Korea

     HQ +82-42-863-2017 

     R&D Center +82-42-861-2017

     Investor Relations +70-4294-6097 

     FAX +82-42-863-2080 

     COPYRIGHT BY PharmAbcine Inc.